TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascendis Pharma ( (ASND) ) has shared an announcement.
Ascendis Pharma released its unaudited condensed consolidated interim financial statements for the period ending September 30, 2025. The company reported a net loss of EUR 60.989 million for the three months ended September 30, 2025, compared to a net loss of EUR 99.198 million in the same period in 2024. Despite the loss, the company showed an increase in revenue to EUR 213.634 million from EUR 57.833 million in the previous year, indicating a significant growth in sales. This financial update may impact the company’s market positioning by highlighting its revenue growth despite ongoing losses, which could influence investor sentiment and strategic decisions moving forward.
The most recent analyst rating on (ASND) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
Ascendis Pharma’s stock score is driven by strong earnings call highlights and positive technical indicators. However, financial performance and valuation concerns due to ongoing losses and reliance on debt financing weigh down the overall score.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies for unmet medical needs. The company specializes in endocrinology and oncology, leveraging its proprietary TransCon technology to create new treatments.
Average Trading Volume: 417,638
Technical Sentiment Signal: Buy
Current Market Cap: $11.87B
For a thorough assessment of ASND stock, go to TipRanks’ Stock Analysis page.